After pharma majors Pfizer and Serum Institute of India (SII), Hyderabad-based Bharat Biotech International Ltd on Monday sought emergency use authorisation from the Drugs Controller General of India (DCGI) for its COVID-19 vaccine, Covaxin. The vaccine is being developed with the Indian Council of Medical Research (ICMR), and is undergoing phase-3 trials in over 25 centres across India. Also read: Vaccine shot ‘painless’, say Covishield trial volunteers“Bharat Biotech today (on Monday) applied for the restricted emergency use of their vaccine. Replying to a query on whether efficacy figure of SII vaccine trials on Indian volunteers is available, head of the National Expert Group on Vaccine Administration V.K. Pfizer India had applied for emergency-use authorisation for its COVID-19 vaccine, after the company's parent received clearance for the treatment from Britain and Bahrain.

Source: The Hindu December 07, 2020 13:10 UTC